Abstract: An autoinjector (1) is disclosed. The autoinjector comprises a main casing (10); a cartridge assembly (30) disposed within the main casing (10). The cartridge assembly may include a cartridge (3) land a needle (40). A power pack (100) is disposed within the main casing (10) for moving the cartridge (31) and the needle (40) from a storage position to an injection position when actuated. An actuation unit (50) comprises a cartridge container (52) and a needle cover (60) disposed between the cartridge container (52) and the main casing (10). The actuation unit (50) is operably coupled to the power pack (110) and retractable from a first position to an actuation position for actuating the power pack. The needle cover (60) is extendable to an extended position covering the needle (40) when the cartridge (31) and the needle (40) are in the injection position. A safety cap (20) is removable from a mounted position on a front end of the main casing (10) to expose a front portion of the actuation unit (50).

Abstract: Disclosed is compositions and pharmaceutically acceptable formulations comprising the four peanut allergens Ara h 1, Ara h 2, Ara h 3, and Ara h 6, as well as a kit comprising the compositions or pharmaceutically acceptable formulations, and methods of their preparation and their use in mitigation of peanut allergy and their uses in peanut allergen-specific immunotherapy.

Abstract: The present invention relates to a method for treating suddenly occurring allergic reactions, such as acute allergic reactions, in a human through administration of a BTK inhibitor. In particular, the present invention relates to a method for emergency treatment of a severe allergic reaction by administration of a BTK inhibitor to said human.

Abstract: An injector is provided for performing an injection operation comprising a housing (104), a needle extendable from a front end of the housing, a rear end of the housing and a longitudinal axis extending between the front end and the rear end, a safety pin (116) in an actuation locked position coupled to the housing and moveable to a safety released position coupled to the housing. The injector is locked against actuation when the safety pin is in the actuation locked position and the injector is ready for actuation of the injection operation when the safety pin is in the safety released position.

Abstract: The invention relates to a pharmaceutical product comprising an allergen extract or an allergoid thereof for the treatment and/or prevention of allergy and allergic asthma caused by house dust mites, which extract comprises at least one extract of mite bodies selected from the following groups a)-b): a) An extract of Der p mite bodies, and b) An extract of Der f mite bodies, and at least one extract of mite cultures selected from the following groups c)-g): c) An extract of Der p faecal particles, d) An extract of Der f faecal particles, e) An extract of Der f whole mite culture, f) An extract of an Der p whole mite culture, and g) a combination of extracts c) to f).

Abstract: The invention relates to novel immunogenic polypeptides identified in house dust mites and storage mites, which have the potential to be used in allergy immunotherapy, for diagnostic purposes, eventually via production of antibodies binding the polypeptide or for characterising allergen extracts of house dust mites and storage mites.

Abstract: The invention relates to a pharmaceutical product comprising an allergen extract or an allergoid thereof for the treatment and/or prevention of allergy and allergic asthma caused by house dust mites, which extract comprises at least one extract of mite bodies selected from the following groups a)-b): a) An extract of Der p mite bodies, and b) An extract of Der f mite bodies, and at least one extract of mite cultures selected from the following groups c)-g): c) An extract of Der p faecal particles, d) An extract of Der f faecal particles, e) An extract of Der f whole mite culture, f) An extract of an Der p whole mite culture, and g) a combination of extracts c) to f).

Abstract: The invention provides allergen containing pharmaceutical products and in particular fast-dispersing solid allergen dosage forms. In particular, fast-dispersing, non-compressed solid dosage forms suitable for oromucosal administration comprising a matrix and at least one allergen are provided. Suitable matrices are gelatine, starch and mannitol. Methods for the dosage forms are also provided.

Abstract: The invention relates to novel immunogenic polypeptides identified in house dust mites and storage mites, which have the potential to be used in allergy immunotherapy, for diagnostic purposes, eventually via production of antibodies binding the polypeptide or for characterising allergen extracts of house dust mites and storage mites.

Abstract: The invention provides allergen containing pharmaceutical products and in particular fast-dispersing solid allergen dosage forms. In particular, fast-dispersing, non-compressed solid dosage forms suitable for oromucosal administration comprising a matrix and at least one allergen are provided. Suitable matrices are gelatine, starch and mannitol. Methods for the dosage forms are also provided.

Abstract: The invention relates to combinations of peptides or variants thereof derived from a portion of an amino sequence of a house dust mite allergen, e.g. the allergens Der p 1, Der f 1, Der p 2 and/or Der f 2. Such peptides comprise at least one T cell epitope and a significant high number of patients in a worldwide population will have HLA alleles with the potential to bind the peptides of the peptide combinations. The invention also relates to the use of such peptide combinations in relieving an immune response caused by a dust mite.

Abstract: The invention relates to combinations of peptides derived from a portion of an amino sequence of a grass pollen allergen, e.g. the allergens Phl p 1, Phl p 2, Phl p 3, Phl p 4 and/or Phl p 5, or a peptide variant thereof. Such peptides comprise at least one T cell epitope mid a high number of patients in a worldwide population will have HLA Class II alleles with the potential to bind the peptides of the peptide combinations. The invention also relates to the use of such peptide combinations in relieving an immune response caused by grass pollen species.

Abstract: An injector is provided for performing an injection operation comprising a housing (104), a needle extendable from a front end of the housing, a rear end of the housing and a longitudinal axis extending between the front end and the rear end, a safety pin (116) in an actuation locked position coupled to the housing and moveable to a safety released position coupled to the housing. The injector is locked against actuation when the safety pin is in the actuation locked position and the injector is ready for actuation of the injection operation when the safety pin is in the safety released position.

Abstract: The invention provides allergen containing pharmaceutical products and in particular fast-dispersing solid allergen dosage forms. In particular, fast-dispersing, non-compressed solid dosage forms suitable for oromucosal administration comprising a matrix and at least one allergen are provided. Suitable matrices are gelatine, starch and mannitol. Methods for the dosage forms are also provided.

Abstract: A composition comprising at least one first allergen, which is a respiratory allergen belonging to a first biological source material group, for use in prophylactic treatment of allergy to at least one second allergen, which is selected from the group consisting of a respiratory and a venomous allergen belonging to a second biological source material group and a food allergen of a food composition, in a subject, wherein the subject has not developed any clinical symptoms of allergy to the first allergen and to the second allergen, and wherein the first and second biological source material groups are not the same.

Abstract: The invention relates to pan pollen immunogens such as polypeptides, proteins and peptides, and methods and uses of such immunogens for modulating or relieving an immune response in a subject. For example, the immunogens can be used for treating a subject for an allergic immune response or inducing or promoting immunological tolerance to the immunogen or a pollen allergen in a subject.

Abstract: The invention relates to a pharmaceutical product comprising an allergen extract or an allergoid thereof for the treatment and/or prevention of allergy and allergic asthma caused by house dust mites, which extract comprises at least one extract of mite bodies selected from the following groups a)-b): a) An extract of Der p mite bodies, and b) An extract of Der f mite bodies, and at least one extract of mite cultures selected from the following groups c)-g): c) An extract of Der p faecal particles, d) An extract of Der f faecal particles, e) An extract of Der f whole mite culture, f) An extract of an Der p whole mite culture, and g) a combination of extracts c) to f).

Abstract: The invention relates to a pharmaceutical product comprising an allergen extract or an allergoid thereof for the treatment and/or prevention of allergy and allergic asthma caused by house dust mites, which extract comprises at least one extract of mite bodies selected from the following groups a)-b): a) An extract of Der p mite bodies, and b) An extract of Der f mite bodies, and at least one extract of mite cultures selected from the following groups c)-g): c) An extract of Der p faecal particles, d) An extract of Der f faecal particles, e) An extract of Der f whole mite culture, f) An extract of an Der p whole mite culture, and g) a combination of extracts c) to f).

Abstract: The invention relates to method for quantification of the absolute amount of allergen in an allergen sample comprising: a) providing a known amount of one or more allergen calibration standard peptide(s) having a sequence of amino acids which is identical with, and optionally unique for, a sequence to be found in the allergen to be quantified and optionally labelling said allergen calibration standard peptide(s), b) degrading the allergen sample to obtain a mixture of peptides, and optionally labelling said peptides with one or more labelling agent(s), wherein at least the peptides in the degraded allergen sample or the calibration standard peptides are labelled, and if both the peptides in the degraded allergen sample and the allergen calibration standard peptide(s) are labelled, the labelling agent(s) used for labelling the allergen calibration standard peptide(s) are different from the labelling agent(s) used for labelling the peptides of the degraded allergen sample, c) quantifying the absolute amount

Abstract: The present invention relates to the use of a seasonal allergen composition for the manufacture of a vaccine formulation for preventing or treating allergy to the allergen composition in a subject by parenteral administration, wherein the vaccine formulation is administered in a dosage regimen comprising an up-dosing phase, wherein the up-dosing phase partly or wholly overlaps with the allergen season of the allergen composition.